v3.25.2

Condensed Consolidated Balance Sheets - USD ($)	Jun. 30, 2025	Dec. 31, 2024
Current assets:
Cash and cash equivalents	$ 53,583	$ 115,019
Prepaid expenses and other current assets	4,116	26,592
Total current assets	57,699	141,611
Total assets	57,699	141,611
Current liabilities:
Accounts payable	133,808	134,865
Accrued compensation	4,011,998	3,767,652
Accrued consulting	787,903	787,903
Accrued expenses and other	636,632	646,850
Loan payable	200,000	200,000
Total current liabilities	5,770,341	5,537,270
Convertible notes, net	1,428,880	1,392,515
Total liabilities	7,199,221	6,929,785
Commitments and contingencies
Stockholders’ deficit:
Preferred stock, value
Common stock, $0.00001 par value: 100,000,000 shares authorized: 7,242,137 shares issued and outstanding	72	72
Additional paid-in capital	2,050,073	2,050,073
Accumulated deficit	(9,191,668)	(8,838,320)
Total stockholders’ deficit	(7,141,522)	(6,788,174)
Total liabilities and stockholders’ deficit	57,699	141,611
Series A Preferred Stock [Member]
Stockholders’ deficit:
Preferred stock, value	0	0
Series B Preferred Stock [Member]
Stockholders’ deficit:
Preferred stock, value	$ 1	$ 1

Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).

Mosaic ImmunoEngineering Inc. 10-Q